Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation

Fifteen patients (13 males and two females; mean age, 63 years; age range, 46–84 years) with multiple myeloma were studied prospectively (range of follow-up period, 2–6 months) to elucidate the diagnostic validity of biochemical markers of bone formation (bone alkaline phosphatase and the C-terminal propeptide of type I procollagen) and bone resorption (urinary excretion of pyridinium cross-links) for monitoring these patients. Eleven of 15 patients received melphalan i.v. and prednisone p.o. every 4 weeks. All patients were given pamidronate i.v. for inhibition of bone resorption. The mean values of the urinary excretion of pyridinium cross-links were significantly higher in the patients fulfilling the criteria of `progression' or `relapse' than in those showing `response' and those in the `plateau phase' ( P0.05). The concentrations of both bone formation markers were significantly lower in the patients than in the samples obtained from apparently healthy persons ( P